Amgen Exec Says Spent $500M In Q2 On Capital Expenditures, Driven By Investments Across U.S. Manufacturing Sites; Continues To Expect Capital Expenditures Of About $2.6B In 2026 To Scale Manufacturing Capacity, Including For Maritide's Launch; Expect A Meaningful Sequential Increase In Operating Expenses In Q3
Amgen Exec Says Spent $500M In Q2 On Capital Expenditures, Driven By Investments Across U.S. Manufacturing Sites; Continues To Expect Capital Expenditures Of About $2.6B In 2026 To Scale Manufacturing Capacity, Including For Maritide's Launch; Expect A Meaningful Sequential Increase In Operating Expenses In Q3
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day